+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
JHS

JHS Svendgaard Laboratories Share Price

 

 

JHS Svendgaard Laboratories live price: ₹8.1. It opened at ₹8 vs previous close ₹8; intraday high/low: ₹8/₹8. The 50 & 200 DMA stand at ₹8.62/₹10.30.

JHS Svendgaard Laboratories Performance

  • Today's Low
  • ₹8
  • Today's High
  • ₹8
  • 52 Week Low
  • ₹6
  • 52 Week High
  • ₹14
  • Open Price₹8
  • Previous Close₹8
  • Volume110,818
  • 50 DMA₹8.62
  • 100 DMA₹9.08
  • 200 DMA₹10.30

JHS Svendgaard Laboratories Chart

Investment Returns

  • Over 1 Month -4.59%
  • Over 3 Month -0.74%
  • Over 6 Month -19.24%
  • Over 1 Year -37.93%

Smart Investing Starts Here Start SIP with JHS Svendgaard Laboratories for Steady Growth!

Invest Now

JHS Svendgaard Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -36.1
  • PEG Ratio
  • -0.4
  • Market Cap Cr
  • 69
  • P/B Ratio
  • 0.4
  • Average True Range
  • 0.54
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.14
  • RSI
  • 43.54
  • MFI
  • 11.41

Latest Stock News Updates

JHS Svendgaard Standalone December 2023 Net Sales at Rs 14.30 crore, down 32.72% Y-o-Y

JHS Svendgaard Standalone June 2023 Net Sales at Rs 14.76 crore, down 23.13% Y-o-Y

JHS Svendgaard Standalone September 2021 Net Sales at Rs 23.06 crore, down 24.03% Y-o-Y

NULL

JHS Svendgaard Laboratories Financials

JHS Svendgaard Laboratories Technicals

EMA & SMA

Current Price
₹8.10
+ 0.1 (1.25%)
pointer
  • Bearish Moving Average 15
  • Bullish Moving Average 1
  • 20 Day
  • ₹8.40
  • 50 Day
  • ₹8.60
  • 100 Day
  • ₹9.10
  • 200 Day
  • ₹10.30

Resistance and Support

8.15 Pivot Speed
  • R3 8.93
  • R2 8.69
  • R1 8.39
  • S1 7.85
  • S2 7.61
  • S3 7.31

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Jhs Svendgaard Labs. has an operating revenue of Rs. 101.69 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of -2% needs improvement, ROE of -1% is poor and needs improvement. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 46 which is a POOR score indicating inconsistency in earnings, a RS Rating of 15 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 111 indicates it belongs to a poor industry group of Cosmetics/Personal Care and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

JHS Svendgaard Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-26 Audited Results
2026-02-10 Quarterly Results
2025-11-14 Quarterly Results
2025-11-13 Quarterly Results
2025-08-21 Employees Stock Option Plan

JHS Svendgaard Laboratories Shareholding Pattern

33.85%
3.6%
46.62%
15.93%

JHS Svendgaard Laboratories FAQs

JHS Svendgaard Laboratories share price is ₹8 As on 18 June, 2026 | 01:01

The Market Cap of JHS Svendgaard Laboratories is ₹69.3 Cr As on 18 June, 2026 | 01:01

The P/E ratio of JHS Svendgaard Laboratories is -36.1 As on 18 June, 2026 | 01:01

The PB ratio of JHS Svendgaard Laboratories is 0.4 As on 18 June, 2026 | 01:01

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23